Financial Performance - Revenue for 2023 reached 854.13 million RMB, a 3.02% increase compared to 2022[8] - Net profit attributable to shareholders decreased by 15.64% to 235.35 million RMB in 2023[8] - Revenue for the reporting period was RMB 854,125,434.83, a 3.02% increase year-over-year[99] - Basic earnings per share (EPS) for 2023 decreased by 15.75% to RMB 2.14 compared to RMB 2.54 in 2022[165] - Diluted EPS for 2023 decreased by 15.42% to RMB 2.14 compared to RMB 2.53 in 2022[165] - Weighted average return on equity (ROE) decreased by 4.33 percentage points to 13.59% in 2023[165] - Revenue and operating net profit both achieved double-digit growth in Q1 2024, with non-GAAP net profit increasing by 27.09% year-over-year[189] - The company's non-recurring profit and loss items totaled RMB 73,506,327.78 in 2023, a significant increase from RMB 62,514,939.23 in 2022[181] R&D and Innovation - R&D investment continues to increase, driving technological innovation and product development[25] - The company's R&D expenses increased due to intensified investment in research and development during the reporting period[75] - R&D expenses increased by 15.58% to RMB 91,762,758.69 compared to the previous year[99] - The company has 340 R&D personnel, accounting for 24.51% of the total workforce[82] - The company is leading the "Ultra-High Resolution Live Cell Imaging Microscope Research and Application" project under the national "14th Five-Year Plan" major scientific instrument initiative[39] - The company established partnerships with Zhejiang University and the Chinese Academy of Sciences, focusing on advanced technologies such as super-resolution microscopy and AI algorithms[197] - The company acknowledges the need for continuous technological innovation and new product development to maintain its competitive edge[138] Market Expansion and International Operations - The company is accelerating overseas market expansion, focusing on emerging and high-end markets[18] - The company has expanded its market presence in India, South Korea, and other international markets, leveraging developed markets as benchmarks for rapid expansion[68] - Overseas assets amount to RMB 50,232,131.45, representing 2.40% of total assets[87] - Export revenue accounted for 46.65% of total revenue, with USD as the primary settlement currency for overseas clients[120] - The company's overseas market share for high-end microscopes increased significantly in 2023, with market teams visiting Europe, Japan, and Singapore[190] - The company is enhancing its international market coordination and overseas marketing capabilities to secure high-quality projects and manage risks effectively[139] - The company faces challenges in international operations due to geopolitical tensions and regional conflicts, which may impact its global brand influence[139] - The company is actively monitoring and managing risks related to its international operations and market environment[139] Product Development and Business Growth - The company has developed multiple high-end medical optical components, including endoscope lenses, surgical mirrors, and detection objectives, contributing to the localization of high-end medical devices[44] - The company's medical optical products, including embedded microscopy systems and digital slide scanners, are gaining traction in markets such as gene sequencing, cancer screening, and gynecological disease detection[53] - The company's medical optics business has grown by over 50% in the past two years, covering more than 70% of key players in the domestic laparoscopic system market[186] - The company's medical optics business revenue reached 63 million RMB in 2023, exceeding the target set in the equity incentive plan[194] - The company successfully developed a 3D 4K fluorescence module for endoscopes and gained customer recognition[194] - The company's barcode scanning business saw sequential growth in each quarter since Q3 2023, with orders from Zebra and Honeywell expected to start mass production in H2 2024[193] - The NSR950 super-resolution microscope achieved its first sale, marking the company's world-class technical level in optical microscopy[192] - The company's NCF series of confocal microscopes now covers products priced between 800,000 RMB and 1.5 million RMB, forming a complete product family[191] - The company's NIB1000 inverted biological microscope began mass sales, with technical indicators ranking among the global advanced level[192] - The high-end microscope brand NEXCOPE series revenue grew from 4 million RMB in 2018 to nearly 140 million RMB in 2023, with a compound annual growth rate exceeding 100%[190] Strategic Partnerships and Industry Leadership - The company has established long-term strategic partnerships with industry leaders such as ZEISS, Leica, Zebra, Honeywell, and Cognex, enhancing its R&D and manufacturing capabilities[45] - The company has led the formulation of 1 international standard and participated in the revision of 108 national and industry standards, along with 3 group standards, establishing itself as a leader in industry standards[55] - The company was nominated for the 5th "China Quality Award" and the 9th "Zhejiang Provincial Government Quality Award," reflecting high recognition from the government and industry[188] - The company has been recognized with the "China Quality Award Nomination" for its contributions to high-precision, automated, and intelligent microscopy development[59] Operational Efficiency and Management - The company invested over 50 million yuan in information technology and automation equipment in 2023, integrating systems like SAP, CRM, PLM, E-HR, MES, WMS, and ESB to enhance management efficiency[27] - The company has established a comprehensive management system, including ISO9001, ISO14001, ISO13485, and IATF16949 certifications, ensuring high-quality production and compliance[72] - The company has implemented a "8090 Plan" to promote younger management teams, with 80s and 90s generations forming the core of middle and senior management, enhancing resource allocation and solution formulation[57] - The company is strengthening its sales, supply chain, and manufacturing processes through informatization to improve output scale and overall operational efficiency[135] - The company is investing in the construction of new factories to support its growth and operational efficiency[136] Cost and Profit Analysis - Gross margin remained stable at around 40% due to deep collaborations with industry leaders like Zeiss and Leica[13] - Non-recurring gains in 2023 included 60.40 million RMB from non-current asset disposals and 33.45 million RMB from government subsidies[10] - Non-current asset disposal gains amounted to RMB 50,216,584.00, contributing 19.94% to total profit[110] - Government subsidies received during the reporting period totaled RMB 33,453,813.29, accounting for 13.29% of total profit[110] - The company's total cost for optical components and microscope series increased by 9.51% year-over-year, with significant increases in raw material costs for microscope series (14.08%) and direct labor costs (39.66%)[79] - Production volume of optical components decreased by 22.55% to 25,181,004 units, while sales volume decreased by 24.75% to 29,323,798 units[102] Future Plans and Strategic Goals - The company completed its IPO fundraising projects, including the LiDAR components project, by January 2024[7] - The "Medical Optical Equipment and Precision Optical Components Production Base" project is expected to complete main structure acceptance and partial decoration by 2024[16] - The company is preparing for potential demand growth following the Chinese government's policy on equipment updates and consumer upgrades in 2024[21] - The company aims to become a globally renowned optical enterprise by 2035, establishing a high-quality image for Chinese scientific instruments worldwide[95] - The company focuses on a "2+2" business layout, emphasizing optical microscopes and barcode machine vision as core businesses, while expanding into emerging sectors like LiDAR and medical optics[135] - The company plans to distribute a cash dividend of RMB 9.55 per 10 shares, totaling RMB 106,167,827.50, representing 45.11% of the net profit attributable to shareholders in 2023[156] - The company's total share capital as of April 25, 2024, is 111,170,500 shares[156] Industry and Market Trends - The global barcode scanner market was valued at $6.94 billion in 2021 and is projected to reach $10.77 billion by 2027, with a CAGR of 7.6%[34] - The company has secured a significant position in the global barcode optical components market, becoming the largest global supplier and expanding into chip packaging and modular product development[71] - The company's optical components business, including barcode machine vision, laser radar, and medical optics, operates on a direct sales model with high customer stickiness and market competitiveness[67] - The company is exposed to risks from macroeconomic slowdown and market fluctuations, which could lead to decreased demand and affect new business development[140]

证券代码：603297 证券简称：永新光学 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 (一)主要会计数据和财务指标 宁波永新光学股份有限公司 2024 年第一季度报告 对公司将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》未列举的项目认 定为的非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 | --- | --- | --- | --- | |-----------------------------------------------|-------|-----------------|----------------------------------------------------------------------------------------- ...

宁波永新光学股份有限公司 2023 年第三季度报告 证券代码：603297 证券简称：永新光学 宁波永新光学股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 项目 本报告期 本报告期 比上年同 期增减变 动幅度(%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 219,892,146.23 12.23 610,644,660.29 0.47 归属于上市公司股东的 净利润 57,869,856.88 -6.97 173,757,453.96 -12.64 归属于上市公司股东的 扣 ...

宁波永新光学股份有限公司 2023 年半年度报告 公司代码：603297 公司简称：永新光学 宁波永新光学股份有限公司 2023 年半年度报告 1 / 148 宁波永新光学股份有限公司 2023 年半年度报告 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2023 年上半年度公司不进行利润分配或公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中描述公司可能存在的相关风险，敬请投资者予以关注，详见本报告第三节 "管理层讨论与分析"章节中关于公司可能面对风险的描述。 十一、 其他 □适用 √不适用 2 / 148 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或 ...

宁波永新光学股份有限公司 2022 年年度报告 公司代码：603297 公司简称：永新光学 宁波永新光学股份有限公司 2022 年年度报告 1 / 197 宁波永新光学股份有限公司 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人毛磊、主管会计工作负责人毛凤莉及会计机构负责人（会计主管人员）毛凤莉 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配 六、 预案或公积金转增股本预案 公司 2022 年度利润分配预案为：公司拟以实施权益分派股权登记日登记的总股本为基数， 向全体股东每 10 股派发现金股利人民币 9.60 元（含税）。截至 2023 年 4 月 21 日，公司总股本 为 110,477,500 股，以此计算合计拟派发现金红利人民币 106,058,400.00 元（含税），剩余未 分配 ...

宁波永新光学股份有限公司 2023 年第一季度报告 证券代码：603297 证券简称：永新光学 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □是 √否 | --- | --- | --- | |------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 188,173,306.31 | -9.96 | | 归属于上市公司股东的净利润 | 47,384,796.49 | -12.26 | | 归属于上市公司股东的扣除非经常性损益的净 | | | | 利润 | 31,270,465.93 | -23.22 | | 经营活动产生的现金流量净额 | 45,184,491.90 | 1,053.34 | | 基本每股收益（元/股） | 0.43 | -12.24 | 1 / 10 | -- ...

宁波永新光学股份有限公司 2022 年第三季度报告 单位：元 币种：人民币 证券代码：603297 证券简称：永新光学 宁波永新光学股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------|----------------|--------------------------------------|----------------|------------------------------------------ ...

公司代码：603297 公司简称：永新光学 宁波永新光学股份有限公司 2022 年半年度报告 宁波永新光学股份有限公司 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人毛磊、主管会计工作负责人毛凤莉及会计机构负责人（会计主管人员）毛凤莉声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2022年上半年度公司不进行利润分配或公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投资 者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告 ...

宁波永新光学股份有限公司 2022 年第一季度报告 单位：元 币种：人民币 证券代码：603297 证券简称：永新光学 宁波永新光学股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 208, ...

公司代码：603297 公司简称：永新光学 宁波永新光学股份有限公司 2021 年年度报告 宁波永新光学股份有限公司 2021 年年度报告 重要提示 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人毛磊、主管会计工作负责人毛凤莉及会计机构负责人（会计主管人员）毛凤莉声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年度利润分配预案为：公司拟以实施权益分派股权登记日登记的总股本为基数，向 全体股东每10股派发现金股利人民币9.00元（含税）。截至2022年4月22日，公司总股本为 110,477,500股，以此计算合计拟派发现金红利人民币99,429,750.00元（含税），剩余未分配利 润结转至以后年度分配。本次公司不送红股，不进行资本公积金转增股本。该预案已经公司第七 届董事会第十六次会议审议通过，尚需提交股东大会审议通过后方可实施。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七 ...